INCLUSION CRITERIA:

PROCUREMENT

Inclusion Criteria:

- Referred patients will initially be consented for procurement of blood for generation
of the transduced CTL Line. Eligibility criteria at this stage include:

- Diagnosis of recurrent HL or NHL, or newly diagnosed patients unable to receive or
complete standard therapy OR diagnosis of relapsed/refractory HL or NHL with a
treatment plan that will include high dose therapy and stem cell transplantation

- CD30 positive tumor (can be pending at this time)

- EBV seropositivity (can be pending at this time)

- Hgb > 8.0

- Informed consent explained to, understood by and signed by patient/guardian.
Patient/guardian given copy of informed consent.

TREAMENT

Inclusion Criteria:

Patients must meet the following eligibility criteria to be
included for treatment:

- Diagnosis - CD30+ HL or CD30+ NHL

- During the dose escalation phase: only adult patients (age 18 and older) with active
disease failing standard therapy

- After dose escalation: any patient (children or adults) with relapsed CD30+ HL or
CD30+ NHL or newly diagnosed patients unable to receive or complete standard therapy
OR diagnosis of relapsed/refractory CD30+ HL or CD30+ NHL with a treatment plan that
will include high dose therapy and autologous stem cell transplantation.

- CD30 positive tumor

- EBV seropositivity.

- Recovered from acute toxic effects of all prior chemotherapy at least one week and 30
days from prior chemotherapy before entering this study.

- Bilirubin 1.5 times or less than upper limit of normal.

- AST 3 times or less than upper limit of normal.

- Serum creatinine 1.5 times or less than upper limit of normal.

- Pulse oximetry of > 90% on room air

- Karnofsky or Lansky score of > 60%.

- Available autologous transduced EBV-specific cytotoxic T lymphocytes with 15% or more
expression of CD30CAR determined by flow-cytometry.

- Adequate pulmonary function with FEV1, FVC and DLCO 50% or greater of expected
corrected for hemoglobin. Exceptions may be allowed for patients with pulmonary
involvement after discussing with PI.

- Sexually active patients must be willing to utilize one of the more effective birth
control methods during the study and for 6 months after the study is concluded. The
male partner should use a condom.

- Patients or legal guardians must sign an informed consent indicating that they are
aware this is a research study and have been told of its possible benefits and toxic
side effects. Patients or their guardians will be given a copy of the consent form.

EXCLUSION CRITERIA:

PROCUREMENT Exclusion Criteria:

- Active infection with HIV, HTLV, HBV, HCV (can be pending at this time).

- Received rituximab within 4 months of blood collection for LCL initiation (unless
circulating CD19+ B are =/>2%)

TREATMENT Exclusion Criteria:

- Currently receiving any investigational agents or received any tumor vaccines within
the previous six weeks.

- Received anti-CD30 antibody-based therapy within the previous 6 weeks.

- History of hypersensitivity reactions to murine protein-containing products.

- Pregnant or lactating.

- Tumor in a location where enlargement could cause airway obstruction.

- Current use of systemic corticosteroids.